Drug repurposing company Isla Pharmaceuticals reported on Monday the receipt of the key patent for its lead Isla101 programme on 29 September 2020 from the Brazilian Industrial Property Office under the Brazil Patent No BR 112015026243-0..
According to the company, Isla101, a drug with a well understood safety profile, is being repurposed for the potential prevention and treatment of mosquito borne (or vector) diseases including dengue, Zika and others that represent major unmet medical needs in Brazil.
Brazil generally has the greatest number of dengue cases in the world, with more than two million cases 2019 alone. The country has also been severely affected by outbreaks of Zika virus and chikungunya in the last few years.
In conjunction with the patent, Isla has licensed an IP portfolio from the Monash University, with focus on the use of molecules for the prevention and treatment of mosquito borne viruses.
The company is advancing Isla101 towards a Phase II clinical trial in dengue-infected subjects and upon US FDA approval and meeting certain other criteria, it may be eligible to obtain a Priority Review Voucher, which will permit to expedite the FDA approval process for a new drug, or sell the PRV in a secondary market. The PRVs reportedly attracts USD75m-USD150m.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT